Medical Marijuana Inc. announced in late July 2017, that the San Diego, CA-based company’s AXIM Biotechnologies was working with an Israel-based contract research organization to begin a clinical proof of concept study (POC) with its cannabidiol and gabapentin chewing gum product to treat restless leg syndrome in patients.
There will be a randomized, double-blind, single-center, phase two trial to demonstrate the efficacy of AXIM’s chewing gum product. Thirty study subjects will be enrolled in Israel.
Restless leg syndrome (RLS), also called Willis-Ekbom disease, is when nocturnal sensorimotor symptoms occur. People with RLS have lower extremity muscle spasms while they are sleeping. This can disrupt their sleep and cause pain. Anywhere from around 4% to 14% of the U.S. population has this condition.
“We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders,” Stuart Titus, PhD, chief executive officer of Medical Marijuana, said in a news statement.